SYNRIBO (omacetaxine mepesuccinate) for Injection

SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).

Home | (omacetaxine mepesuccinate) for Injection

SYNRIBO (omacetaxine mepesuccinate) for Injection Price In India and Overseas
SYNRIBO (omacetaxine mepesuccinate) for Injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

SYNRIBO (omacetaxine mepesuccinate) for Injection

Omacetaxine mepesuccinate is approved to treat: Chronic myelogenous leukemia. Omacetaxine mepesuccinate is also being studied in the treatment of other types of cancer.

Synribo, A drug used to treat adults with certain types of chronic myelogenous leukemia that cannot be treated with tyrosine kinase inhibitors (a type of anticancer drug) or that have not gotten better after treatment with at least two tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Synribo blocks certain proteins involved in cell growth and may kill cancer cells. It is a type of plant alkaloid and a type of protein synthesis inhibitor. Also called homoharringtonine and omacetaxine mepesuccinate.

Omacetaxine Mepesuccinate, A drug used to treat adults with certain types of chronic myelogenous leukemia that cannot be treated with tyrosine kinase inhibitors (a type of anticancer drug) or that have not gotten better after treatment with at least two tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Omacetaxine mepesuccinate blocks certain proteins involved in cell growth and may kill cancer cells. It is a type of plant alkaloid and a type of protein synthesis inhibitor. Also called homoharringtonine and Synribo.

Drug (Brand / Generic): SYNRIBO / omacetaxine mepesuccinate
Current Indications: chronic lymphocytic leukemia (CLL)
Marketed by:: Teva Pharmaceutical USA, Inc.
Approval Date: 2012

Available as (Form & Strength): Single-use vial containing 3.5 mg of omacetaxine mepesuccinate as a lyophilized powder. SYNRIBO (omacetaxine mepesuccinate) for Injection is supplied in 8 mL clear glass single-use vial in individual cartons. Each vial contains 3.5 mg of SYNRIBO (omacetaxine mepesuccinate) for Injection (NDC 63459-177-14).

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.